Table 3.
Epidemiological characteristics of patients and specimens in the three clusters based on mgpB typing.
| Cluster A | Cluster B | Cluster C | p A-B a | p A-C b | p B-C c | |
|---|---|---|---|---|---|---|
|
Total number of patients
(n = 370) |
149 | 80 | 141 | |||
| Cohorts | ||||||
| MSM | 17 (11.4%) | 9 (11.3%) | 39 (27.7%) | 0.971 | <0.001 | 0.004 |
| Women | 132 (88.6%) | 71 (88.7%) | 102 (72.3%) | |||
| Geographical origin | ||||||
| Metropolitan France | 67 (45.0%) | 51 (63.8%) | 78 (55.3%) | 0.007 | 0.078 | 0.222 |
| Overseas France | 82 (55.0%) | 29 (36.2%) | 63 (44.7%) | |||
|
Total number of specimens
(n = 374) |
150 | 81 | 143 | |||
| Specimen type | ||||||
| Vaginal swab | 115 (76.7%) | 61 (76.3%) | 83 (58.0%) | 0.400 | <0.001 | 0.021 |
| Urine | 28 (18.7%) | 12 (15.0%) | 33 (23.1%) | |||
| Rectal swab | 7 (4.6%) | 7 (8.7%) | 27 (18.9%) | |||
| Macrolide resistance | ||||||
| Resistant | 30 (20.0%) | 24 (29.6%) | 54 (37.8%) | 0.099 | <0.001 | 0.220 |
| Susceptible | 120 (80.0%) | 57 (70.4%) | 89 (62.2%) | |||
| Fluoroquinolone resistance | ||||||
| Resistant | 17 (12.5%) | 13 (17.8%) | 11 (8.3%) | 0.297 | 0.256 | 0.041 |
| Susceptible | 119 (87.5%) | 60 (82.2%) | 122 (91.7%) | |||
ap value for χ2 tests between Clusters A and B. b p value for χ2 tests between Clusters A and C. c p value for χ2 tests between Clusters B and C.